Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Recruiting

Phase 2

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCCActivity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Sponsor:

Flamingo Therapeutics NV

Code:

NCT05814666

Conditions

HNSCC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Danvatirsen

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-02. This information was provided to ClinicalTrials.gov by Flamingo Therapeutics NV on 2025-03-25.